Quince Therapeutics, Inc.

NasdaqGS QNCX

Quince Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -34.43 M

Quince Therapeutics, Inc. EBITDA is USD -34.43 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -37.76% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Quince Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -24.99 M, a 63.36% change year over year.
Quince Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -68.21 M, a 21.58% change year over year.
Quince Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -86.98 M, a -24.09% change year over year.
Quince Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -70.10 M, a -137.19% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: QNCX

Quince Therapeutics, Inc.

CEO	Dr. Dirk Thye M.D.
IPO Date	May 9, 2019
Location	United States
Headquarters	601 Gateway Blvd
Employees	32
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Key trends

Past 5 years